Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Extra

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Bone Marrow Transplantation|November 1, 1996
Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancerC Gisselbrecht, J M Extra, J P Lotz, et al.
British Journal of Cancer|November 27, 2001
High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II studyP H Cottu, J M Extra, M Espie, et al.
British Journal of Cancer|November 15, 2000
Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancerJ Y Pierga, E Mouret, V Diéras, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reactionP de Cremoux, J M Extra, M G Denis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Concomitant chemoradiotherapy followed, where feasible, by surgery for cancer of the esophagusG Ganem, B Dubray, Y Raoul, et al.
BMC Cancer|October 16, 2015
Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective studyS Rahal, J M Boher, J M Extra, et al.
British Journal of Cancer|February 27, 2014
Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimenS Giacchetti, R Porcher, J Lehmann-Che, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer studyX Pivot, J P Spano, M Espie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapyP Rougier, R Bugat, J Y Douillard, et al.
Bone Marrow Transplantation|April 5, 2016
Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantationL Boudin, A Gonçalves, R Sabatier, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Bone Marrow Transplantation|November 1, 1996
Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancerC Gisselbrecht, J M Extra, J P Lotz, et al.
British Journal of Cancer|November 27, 2001
High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II studyP H Cottu, J M Extra, M Espie, et al.
British Journal of Cancer|November 15, 2000
Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancerJ Y Pierga, E Mouret, V Diéras, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reactionP de Cremoux, J M Extra, M G Denis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Concomitant chemoradiotherapy followed, where feasible, by surgery for cancer of the esophagusG Ganem, B Dubray, Y Raoul, et al.
BMC Cancer|October 16, 2015
Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective studyS Rahal, J M Boher, J M Extra, et al.
British Journal of Cancer|February 27, 2014
Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimenS Giacchetti, R Porcher, J Lehmann-Che, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer studyX Pivot, J P Spano, M Espie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapyP Rougier, R Bugat, J Y Douillard, et al.
Bone Marrow Transplantation|April 5, 2016
Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantationL Boudin, A Gonçalves, R Sabatier, et al.
Pageof 9